We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » REMS Evaluations Not Perfect, FDA Questions Assessment Methods
REMS Evaluations Not Perfect, FDA Questions Assessment Methods
May 11, 2012
The FDA is questioning surveys and other assessment methods drugmakers are using to evaluate whether risk evaluation and mitigation strategies (REMS) work. An initial review shows several shortcomings.